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Abstract
Background: Due to therapeutic implications with regard to both efficiency and safety of chemotherapy agents
it is important to differentiate between subtypes of NSCLC. Up to today we experience a continuous reservation
regarding the use of fine needle aspiration cytology. The aim of the present study is to estimate the value of
cytologic criteria for lung cancer typing on small biopsies independent from all possible technique failures.
Methods: Between January 1997 and December 2008 760 intraoperative FNAC- (fine needle aspiration cytology)
specimens from 702 patients have been examined. Cytologic evaluation and immediate communication of results
to the surgeons followed. Afterwards, intraoperative cytologic findings were compared with final histologic
diagnoses of the resected specimens.
Results: Intraoperative cytologic analysis yielded a sensitivity of 94.8 %, a specificity of 98.8 %. An overall positive
predictive value of 99.8 % with respect to final histologic analysis of primary lung cancer was achieved. The highest
value could be reached for adenocarcinomas, followed by carcinoids and squamous cell carcinomas.
Conclusions: Lung cancer typing according to cytologic criteria is feasible and accurate as well as comparable with
results of histologic analysis on small specimens. Herewith, clinicians can come up to the increasing demands on
minimally invasive harvested specimens with regard to therapeutic implications.
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Background
Most lung cancer patients present in advanced inoperable
stages and the diagnosis is based on small specimens, like
small forceps or needle biopsies and/or cytology. In
addition to new biopsy techniques, especially in com-
bination with ultrasound, a paradigm shift has occurred
for both pathologists and clinicians [1, 2].
With respect to this shift there is an increased signifi-
cance of cytologic aspects regarding biopsy procedures
themselves as well as morphologic analysis [3].
Furthermore, due to important therapeutical implica-
tions e.g. concerning chemotherapy regimens in contrast
to former times it is not only important to distinguish
between SCLC and NSCLC but also between their sub-
types of squamous cell carcinomas and adenocarcinomas.
Several chemotherapy agents have become part of clinical
daily routine with indication contingent on definition of
subtype, with regard to both efficiency and safety [4]. For
example, EGFR mutations, which are predominantly
found in adenocarcinomas, are a prerequisite for the
application of EGFR tyrosine kinase inhibitors. Other
current agents like bevacizumab and pemetrexed are only
approved for patients with non-squamous cell carcinomas
due to specific toxicity and effectiveness.
In the 2004 WHO classification of lung tumors, cy-
tology was addressed for the first time, but subclassifica-
tion on small biopsies was not taken into account.
Methodical difficulties of tumor typing on FNAC
specimens are comparable with those on small biopsies
like core and transbronchial biopsies.
* Correspondence: cbiancosino@gmx.de
1Department of Cardiac, Thoracic, Transplantation and Vascular Surgery,
Medical School Hannover, Hannover, Germany
2Department of Thoracic Surgery, Helios University Hospital Wuppertal,
University Witten/Herdecke, Heusnerstraße 40, 42115 Wuppertal, Germany
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Biancosino et al. Diagnostic Pathology  (2016) 11:59 
DOI 10.1186/s13000-016-0510-6
FNAC, especially in combination with ultrasound is
usually the first choice of diagnostic procedures in lung
cancer. Its utility in the diagnosis of endobronchial, per-
ipheral, and mediastinal lesions has been reported and
confirmed in various clinical reports [5, 6]. Most current
papers put their emphasis on sensitivity, specificity and
diagnostic reliability of FNAC in the diagnosis of malig-
nant tumors. The specificity in these reports is usually
very high.
The most important factors that influence FNAC in-
clude localization of lesions, length and diameter of the
needle as well as the individual kind of biopsy procedure
(percutaneous FNA, CT- or ultrasound guided FNA,
TBNA (transbronchial needle aspiration), EBUS- or
EUS-FNA) [7].
However, in practice there are continuous reservations
using the results of fine needle aspiration cytology. In
this direction the general problems will be well illus-
trated by the question by Langer et al. “Can we use
cytologic diagnosis?” and its reply in JCO by Fischer
et al. [8, 9].
In practice faults in biopsy techniques are generally
interpreted as failure of cytology. Such a wholesale
judgement analysis prevents a correct assessment of the
methodical limitation of different biopsy techniques as
well as the critical judgement of cytological procedures.
FNAC during thoracic surgery is a suitable model to
determine the efficiency of lung cancer typing on small
biopsies. The possibility of minimizing sampling errors is
quite different regarding the individual biopsy procedure
and accounts for the different values of sensitivity [10].
Interestingly, intraoperatively harvested FNAC speci-
mens are less influenced by technique of biopsy than the
above mentioned. For example, due to direct digital
identification of tumors, sampling errors can be nearly
excluded. Furthermore, there is comprehensive feedback
of the biopsy by following on site cytologic analysis and
by final histologic diagnosis of the resected specimen.
Thus, methodic limitations such as incorrect needle
placement, large amounts of fibrous material, scanty cel-
lularity of tissue, as well as improper smear preparation,
which are commonly regarded to account for most false
negative FNAC findings on ultrasound biopsies, can be
avoided intraoperatively.
In contrast to false negative FNAC findings, a false-
positive diagnosis is generally related to the interpret-
ation of the aspirates. In such cases a cytologist attempts
to interpret scant material that contains only few abnor-
mal cells. However, intraoperatively harvested FNAC
specimens contain large numbers of cancer cells and
small tissue fragments.
The aim of the present study is to estimate the value
of cytologic criteria for lung cancer typing on small bi-
opsies independent from all possible technique failures.
Methods
At our hospital, a total of 760 FNAC-specimens from 702
consecutive patients (454 males, 248 females; mean ± SD
age 62.0 ± 9.8 years) were evaluated between January 1997
and December 2008.
Included were all patients with an extensive, preopera-
tive, bronchoscopic work up with EBUS and/or EUS fine
needle aspirations in whom the dignity of tumor could
not be specified.
For intraoperative biopsy procedures Yale-Spinal-Needles
by Becton Dickinson GmbH (Heidelberg, Germany) were
used. All surgeons and nurses in the OR were trained in
optimal smear preparation.
Slide preparation
An optimal smear preparation allows the distribution of
well-preserved cells and small tissue fragments on the
slide.
It was important to prepare a thin and uniform smear
with well-preserved cells and small tissue fragments.
Spraying, squeezing artifacts and blood clots were avoided,
as all this distorts the architecture of cell clusters and may
conceal microscopic details. For each bioptic procedure
the needle was inserted at least two times. Air-dried
smears were fixed in 95 % methanol and stained with
Giemsa (staining solution according to Schlüter).
Following main cytologic features for smear prepara-
tions for the different types of lung cancer were used:
Squamous Cell Carcinoma: Single pleomorphic cells
and syncytial sheets of cells with sharp cytoplasmic
outlines and abnormal cytoplasmic thinning manifested
as caudate and spindle cells. Nuclei are irregularly
shaped and centrally located. Chromatin is coarsely
granular. Keratinized squamous ghosts in a background
of debris and blood.
Adenocarcinoma: Large, three-dimensional cell groups
appear in spherical or oval clusters, and acini with
single cells. Individual cubical or columnar configured
tumor cells, with basophilic or vacuolated cytoplasm.
One or more prominent nuclei are present. Nuclei
are eccentrically placed. Chromatin is finely granular
to dusty.
Large-Cell Carcinoma: A mixture of large, single cells
and syncytial groups with large, and round to oval-
shaped nuclei can be seen. Chromatin is intermediate
between squamous carcinoma and adenocarcinoma.
Small-Cell Carcinoma: Cells occur in small clusters,
clumps, and single cells with intercellular moulding.
Apoptotic cells, mitotic figures, nuclear moulding and
single-file pattern are frequently encountered. Nuclei
vary from round to very irregular with salt-and-pepper
chromatin (PAP). The background is filled with individual
cell necrosis seen as small, dark, pyknotic nuclei [11].
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Carcinoid tumor: Cells appear in small monolayer
clusters, and single cells without intercellular moulding.
No apoptotic cells and mitotic figures can be observed.
Nuclei vary from round to uniformly oval. Sometimes
small protuberances can be observed. As in other
neuroendocrine tumors a salt-and-pepper chromatin
is typical.
Data analysis
Sensitivity, specificity and diagnostic reliability were
computed as usual.
Results
In total 702 consecutive cases were analyzed. Adenocar-
cinoma was the most frequent diagnosis and made up
47.9 of all cases. The other major diagnoses in descending
order of frequency were squamous cell carcinomas
(20.1 %), large cell/large cell neuroendocrine carcinomas
(12.8 %), and benign lung processes (12.8 %) (Table 1).
Cytologically 126 cases were classified as benign, 563
as malignant and 13 cases suspicious of malignancy.
Among the cytologically benign cases 37 were deter-
mined malignant in final histologic analysis. 28 cases of
this collective were malignant lung tumors in the final
interpretation, 9 cases were assessed as non primary lung
tumors (Tables 2 and 3). Cytologically, in 11 cases un-
suspicious lung parenchyma, lymph nodes or bronchial
epithelium was seen, in 8 cases a severe inflammation,
in 2 cases only blood fragments could be identified. In
5 cases of highly differentiated adenocarcinomas it was
not possible to differentiate between reactively altered
pneumocytes type II, adenomatous hyperplasia or highly
differentiated adenocarcinomas. In 3 cases it was not
possible to specify the dignity of tumors later determined
as malignant mesenchymal tumors (Fig. 1)
One patient with a chronic inflammatory process and
one case of lipomatous atrophic thymic tissue were
judged cytologically as malignant and suspicious of ma-
lignancy, respectively. In summary, rapid intraoperative
cytolgic evaluation yielded a sensitivity of 94.8 %, a spe-
cificity of 98.8 %.
The communication to the surgeon included the cyto-
logical judgement (benign, malignant, suspicious) and in
case of malignancy the classification as either primary or
metastatic lung tumor and concerning the latter its ori-
gins. Additionally, a detailed evaluation was given in case
of benign lesions or lesions suspicious of malignancy in
order to facilitate surgical decision making.
Using conventional Giemsa staining only, an overall
positive predictive value of 99.8 % with respect to final
histologic analysis of primary lung cancer was achieved.
The highest value could be reached for adenocarcinomas
(88 %), followed by carcinoids (77 %) and squamous cell
carcinomas (74 %). Diagnosis of adeno-carcinomas had
lower sensitivity than squamous cell carcinomas (71 %
versus 78 %, respectively). The specificity was lower as
well (91 % versus 93 %, respectively) (Table 4).
When all cytological criteria of lung cancer types were
fulfilled levels for sensitivity and specificity were much
higher especially for squamous cell carcinomas and
adenocarcinomas (Tables 5 and 6).
In addition to primary lung tumors secondary pul-
monary lesions were documented to create a compar-
able overall accuracy. Best results could be shown for
malignant melanomas, adenocarcinomas and large cell
carcinomas (Table 7).
Regardless of high specificity a correct subclassifica-
tion of benign lesions by rapid cytologic assessment
was not as accurate as the typification of malignant
tumors.
Discussion
In recent years our concepts of lung cancer have under-
gone a revolution.
Table 1 Results of intraoperative fine needle aspiration cytology of malignant lung tumors and benign lung lesions. Number of all
histological diagnoses compared with corresponding and different cytological findings
Cytological findings Final histological diagnosis
SQC SCLC ADC ADC/SQC LC/LNC Carcinoid Other Benign Total
SQC 98 0 19 4 11 0 0 0 132
SCLC 1 7 1 0 3 1 0 0 13
ADC 7 0 210 3 18 1 0 0 239
LC/LNC 13 1 48 0 39 1 1 0 103
Carcinoid 0 0 3 0 1 13 0 0 17
Other 0 0 1 0 2 0 0 1 4
Susp. 2 0 7 0 2 0 0 1 12
Benign 6 0 14 1 5 2 0 84 112
Total 127 8 303 8 81 18 1 86 632
Abbreviations: SQC Squamous cell carcinoma, SCLC Small Cell Lung Carcinoma, ADC Adenocarcinoma, ADC/SQC Adeno-squamous carcinoma, LC/LNC Large Cell
Carcinoma/Large Cell Neuroendocrine Carcinoma, Other Other malignant tumor, Susp. tumor suspicious findings
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Due to therapeutic implications with regard to both
efficiency and safety of several chemotherapy agents it
is not only important to distinguish between SCLC and
NSCLC but also to give information about the specific
subtype of NSCLC [4]. In contrast to Edward’s et al.
postulation this subtyping is not only possible but in-
dispensable [12]. Although from our point of view the
WHO criteria cannot be consulted for the analysis of
cytologic specimens, a percentage of 40 % or more re-
garding non-small cell lung cancer - not other classified
(NSCLC-NOS) seems no longer acceptable.
As most lung cancer patients are seen in advanced
inoperable stages nowadays the diagnosis is primarily
based on small biopsy or cytology specimens. The ad-
vantage of cytologic diagnosis is that it is based on small
specimens that can be harvested easily by minimally
invasive procedures like EBUS-FNA, TBNA or EUS.
Unfortunately, a histologic confirmation of these cyto-
logic diagnoses is missing. Several studies have confirmed
the excellent accuracy of cytology regarding differentiation
between SCLC and NSCLC [13, 14].
The majority of the published data on techniques like
EBUS, EUS or percutaneous FNA analyze the sensitivity
and specificity of FNA with regard to lung cancer in
general. When it comes to the subtyping of non-small
cell lung cancer by means of cytological procedures,
however, comprehensive reviews on large collectives are
rare [7, 15].
FNAC during thoracic surgery is a suitable model to
determine the efficiency of lung cancer typing on small
biopsies. This study represents an assessment of inde-
pendent morphologic cytology criteria based on a large
collective.
Altogether, our intraoperative cytologic assessment of
benign and malignant tumors yielded a sensitivity of
94.8 %, a specificity of 98.8 %.
The correct subclassification of benign lesions by rapid
cytologic assessment was not as accurate as the typing
of malignant tumors.
Generally speaking intraoperatively harvested fine nee-
dle aspiration biopsies are an excellent model to investi-
gate the difficulties involved in the morphologic analysis
of rapid evaluation and the evaluation of cytologic cri-
teria for the identification of tumor typing without sup-
plementary immunocytochemical procedures.
The fundamental histologic evaluation criterion for
these two-dimensional samples is the detection of inva-
sive and destructive tumor growth. In case of small biop-
sies, punch biopsies and tumor fragments, however, this
method is much less effective. If invasive and destructive
tumor growth cannot be detected evaluation is based
only on a limited number of cytologic criteria.
In contrast to histology, the cytologic diagnosis is
based on the evaluation of single cells, cell clusters and
small, frequently three dimensional tissue fragments.
Preserved tissue architecture is not essential but mostly
also available for cytologic assessment. However, cyto-
logic diagnosis is primarily based on thorough evalu-
ation of a variety of different cytologic criteria on these
single cells, cell clusters and small, frequently three di-
mensional tissue fragments.
In general, the accuracy of tumor diagnosis from fro-
zen sections is very high. Xu et al. reported a sensitivity
and specificity of 100 % in the diagnosis of pulmonary
nodules [15]. However, with regard to rare diseases, it
remains doubtful if only 229 cases, which is comparable
to most studies in this field, are sufficient to draw sub-
stantiated or statistically significant conclusions [16, 17].
When considering a broad spectrum of diseases and a
sufficient case load as achieved in the study by Hwang et
al., more than 24 (0.54 %) false positive, 65 (1.47 %) false
negative and 30 (0.77 %) deferred diagnoses are docu-
mented [18]. Our results are comparable to those shown
by Orki et al. [19].
Overall, cytologic procedures are nearly as accurate as
frozen section but they have limitations especially in tissues
with sparsely scattered cells and with abundant stromal
components. Nevertheless, an accurate evaluation regar-
ding the distribution of single cells and the architecture of
three dimensional tissue fragments allowed for valuable
Table 3 Results of intraoperative fine needle aspiration cytology
of malignant tumors (other than primary lung cancer).
Description of the 9 false negative cases
Cytological findings Final histological diagnosis
SAR ADC Total
Normal tissue 1 2 3
Benign mesenchymal lesion 3 0 3
Blood 1 2 3
Total 5 4 9
Abbreviations: SAR Sarcoma, ADC Adenocarcinoma
Table 2 Results of intraoperative fine needle aspiration cytology
of malignant lung tumors and benign lung lesions. Description
of the 28 false negative cases
Cytological findings Final histological diagnosis
SQC ADC LC/LNC Carcinoid Total
Normal tissue 2 6 0 2 10
Necrosis 0 1 2 0 3
Restenotic pneumonia 4 1 1 0 8
High differentiated tumors 0 5 0 0 5
Dysplasie 1 0 0 0 1
Blood 0 1 5 0 1
Total 7 14 8 2 28
Abbreviations: SQC Squamous cell carcinoma, ADC Adenocarcinoma, LC/LNC
Large Cell Carcinoma/Large Cell Neuroendocrine Carcinoma
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conclusions on the assumed corresponding tissue texture
in situ due to their correlating arrangements. In squamous
cell carcinoma, for example, a multilayered tumor growth
and keratinization are predominantly observed, whereas in
other tumor types, glandular or papillary as well as neuro-
endocrine features were predominantly found. In the ma-
jority of cases a differentiation between squamous cell and
adenocarcinoma can already be achieved by morphology.
The difficulty arises in samples which are poorly differenti-
ated, scant or poorly preserved.
Although during rapid intraoperative evaluation fur-
ther cuts cannot be produced and immunohistochemical
analyses can only be performed to a certain extent, a
high accuracy level regarding the typing of primary and
secondary malignancies seems to be possible [20].
For primary lung cancers we were able to achieve an
overall positive predictive value of 99.8 % with respect to
final histologic analysis. The highest value could be reached
for adenocarcinomas (88 %), followed by carcinoids
(77 %) and squamous cell carcinomas (74 %). Diagnosis
of adenocarcinomas had lower sensitivity than squamous
cell carcinomas (71 % versus 78 %, respectively). The speci-
ficity was lower as well (91 % versus 93 %, respectively).
The rather low levels especially for adenocarcinomas
may be due to several reasons. First of all it is well
known that poorly differentiated tumors are difficult to
classify cytologically.
Levels for sensitivity and specificity were much higher,
squamous cell carcinomas and adenocarcinomas (Table 6),
when tumors in which not all cytological criteria are
fulfilled were excluded.
Our results correspond to investigations that studied
the correlations between FNAC based predictions of
tumor classification and subsequent histologic diagnosis.
Correlations between 62 % and 100 % have been de-
scribed. The highest levels of agreement were docu-
mented for squamous cell carcinoma, SCLC and
adenocarcinoma [7, 21, 22].
Fig. 1 Intraoperative Fine Needle Aspirations in cases of false negative cytological diagnosis. Tumor cells of a finally high differentiated
adenocarcinoma (bronchiolo-alveolar cell type, a Giemsa, 630x). Infiltration of malignant mesenchymal cells of a fibrosarcoma. b Giemsa
staining of tumor in high magnification (630x). Necrotic area from the center and squamous epithelial cell dysplasia in the surrounded
neighborhood of a finally squamous cell carcinoma (c and d)
Table 4 Calculated sensitivity, specificity, false positive, false negative and true positive rates, negative and positive predictive values
(tumor suspicious lesions excluded)
All SQC SCLC AD LC Carcinoid
Sensitivity 94.8 % 78.4 % 87.5 % 70.9 % 49.4 % 72.2 %
Specificity 98.8 % 93.1 % 99.0 % 91.0 % 88.2 % 99.3 %
False positive rate 1.2 % 6.9 % 1.0 % 9.0 % 11.8 % 0.7 %
False negative rate 5.2 % 21.6 % 12.5 % 29.1 % 50.6 % 27.8 %
Negative predective value 75.0 % 94.5 % 99.8 % 77.4 % 92.3 % 99.2 %
Positive predective value 99.8 % 74.2 % 53.8 % 87.9 % 37.9 % 76.5 %
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Secondly, with the advent of selective chemotherapeu-
tics the distinction of adenocarcinomas and squamous
cell carcinomas became more and more important. This
was accomplished by immunohistochemistry as a power-
ful tool for differentiation of unclassifiable cases that in
the past were often defined as NSCLC-not otherwise
specified (NSCLC-NOS) [3, 23].
Another potential contributing factor to our low levels
of accuracy with regard to adenocarcinomas is the fact
that we did not use immunohistochemistry for further
differentiation as for surgical decision making a proof or
an exclusion of NSCLC was sufficient.
It also has to be kept in mind that we did not make
use of the NSCLC-NOS class but always strived after a
definite diagnosis.
Thirdly, according to several studies in cases of ade-
nocarcinomas the heterogeneity of the tumor is re-
sponsible for non coinciding diagnoses rather than
cytologic misdiagnoses. It must not be neglected that
a fine needle aspiration and its cytologic analysis is al-
ways a snap-shot of a small part of the tumor. The
histologic processing of the sample, however, can
identify different differentiation patterns of the tumor
and comes to a diagnostic conclusion respective of its
predominant differentiation.
Intraoperative sampling error, though rarely observed,
cannot be excluded. This leads to the fact that “the false
positive rate of intraoperative cytology should approach
zero, similar to frozen section analysis; however, the lack
of histologic tissue orientation increases the chance for
false negative rate” [24].
Our data corroborate that not only the tumor
localization in the lung parenchyma and the harvesting
technique influence the degree of sampling error but
also to a lesser extent the tissue texture. Thus, these
are the factors that account for the sensitivity of FNAC.
On the other hand, cytologic analysis is the most rele-
vant factor for specificity. The extent of specificity, how-
ever, is essentially influenced by the composition of the
included collective. Our collective with its large number
of patients and its broad spectrum of diseases represents
a realistic image of potential diagnostic difficulties in
daily clinical routine. Additionally, this data base makes
it possible to draw conclusions concerning diagnostic
limitations when using different bioptic techniques such
as EBUS- or EUS-FNAC.
Nevertheless it must be acknowledged that in contrast
to bronchoscopically harvested specimens, our surgical
specimens represent a selection of undistinguishable
tumors whose dignity could obviously not be clarified
Table 5 Results of intraoperative fine needle aspiration cytology of malignant lung tumors (cytological criteria for lung cancer
typing fulfilled) and benign lung lesions. Number of all histological diagnoses compared with corresponding and different
cytological findings
Cytological findings Final histological diagnosis
SQC SCLC ADC ADC/SQC LC/LNC Carcinoid Other Benign Total
SQC 47 0 9 1 6 0 0 0 63
SCLC 0 3 1 0 3 0 0 0 7
ADC 1 0 107 1 3 0 0 0 112
LC/LNC 0 0 1 0 1 0 0 0 2
Carcinoid 0 0 3 0 1 13 0 0 17
Other 0 0 0 0 1 0 0 0 1
Susp. 0 0 1 0 0 0 0 0 1
Benign 6 0 14 1 5 2 0 84 112
Total 54 3 136 3 20 15 0 84 315
Abbreviations: SQC Squamous cell carcinoma, SCLC Small Cell Lung Carcinoma, ADC Adenocarcinoma, ADC/SQC Adeno-squamous carcinoma, LC/LNC Large Cell
Carcinoma/Large Cell Neuroendocrine Carcinoma, Other Other malignant tumor, Susp. tumor suspicious findings
Table 6 Calculated sensitivity, specificity, false positive, false negative and true positive rates, negative and positive predictive values
(tumor suspicious lesion excluded)
All SQC SCLC ADCa LC Carcinoid
Sensitivity 87.8 % 87.0 % 100.0 % 79.3 % 33.3 % 86.7 %
Specificity 100.0 % 93.8 % 98.7 % 97.2 % 99.7 % 98.7 %
False positive rate 0.0 % 6.2 % 1.3 % 2.8 % 0.3 % 1.3 %
False negative rate 12.2 % 13.0 % 0.0 % 20.7 % 66.7 % 13.3 %
Negative predective value 75.0 % 97.2 % 100.0 % 86.1 % 99.4 % 99.3 %
Positive predective value 100.0 % 74.6 % 42.9 % 95.5 % 50.0 % 76.5 %
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by means of minimally invasive procedures so that a
surgical evaluation had to follow. As a matter of fact,
SCLC were underrepresented and adenocarcinomas
were overrepresented in these collectives.
Our series documented only one chronic inflammatory
process that was falsely judged cytologically to be malig-
nant and one case of lipomatous atrophic thymic tissue
that was falsely judged cytolgically suspicious of tumor.
These findings emphasize cytology’s well-known limita-
tions with respect to mesenchymal neoplasms and highly
heterogeneous tumors.
The error of cytologic false-positive diagnoses of can-
cer is generally based on the overinterpretation of only a
few atypical cells.
At the same time it should be emphasized, as shown
by Pedio et al. [25], that mesenchymal tumors or lesions
of suspicious dignity that are difficult to assess cytologic-
ally are also difficult to diagnose histologically.
Sensitivity and specificity are only part of the broader
concept of diagnostic accuracy in cytology. This does
not only entail the assessment of presence or absence of
cancer in a given specimen but also the prediction of
cancer differentiation and the identification of benign
disease states. The difficult area in which cancer can nei-
ther be diagnosed conclusively nor excluded is the area
in which frozen section is irreplaceable.
Advanced investigations on the ultrastructure of lung
tumors have strengthened the importance of cytology.
Bibbo et al. elaborated on this issue stating that in some
situations cytologic interpretation is “more accurately re-
flective of the nature of the lesion than the tissue exam-
ined” [26]. This has been supported by several studies
identifying a significant cellular heterogeneity present in
most of NSCLC and mesenchymal neoplasms. This
holds particularly true for large cell carcinoma and
poorly differentiated carcinomas regardless if of aden-
omatous or squamous differentiation [27, 28].
Conclusions
Intraoperative fine needle aspiration cytology is a valu-
able, low invasive, time and cost saving diagnostic tool
to define the diagnosis of unexplained lung lesions. The
degree of differentiation, growth pattern and/or hetero-
geneity of different lung cancer types determined the re-
liability of cytological diagnosis. Lung cancer typing
according to cytologic criteria is feasible and accurate as
well as comparable with results of histologic analysis on
small biopsy specimens.
Abbreviations
EBUS, endobronchial ultrasound; EGFR, epidermal growth factor receptor;
EUS, endoscopic ultrasound; FNAC, fine needle aspiration cytology; NSCLC,
non small cell lung cancer; NSCLC-NOS, non-small cell lung cancer - not
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